Optimal dose of losartan for renoprotection in diabetic nephropathy
نویسندگان
چکیده
منابع مشابه
Optimal dose of losartan for renoprotection in diabetic nephropathy.
BACKGROUND Angiotensin II subtype-1 receptor antagonists represent a valuable new class of drugs in the treatment of diabetic nephropathy. The aim of our study was to evaluate the optimal dose of losartan for renoprotection and blood pressure reduction in diabetic nephropathy. METHODS Fifty consecutive hypertensive type 1 diabetic patients with diabetic nephropathy received increasing doses o...
متن کاملDiabetic nephropathy: evidence for renoprotection and practice.
Patients with diabetic renal disease have a very bad prognosis. Hyperfiltration, related to poor metabolic control, occurs early on in the disease process. There is also an increase in albumin excretion which can be readily reversed by eVective glycaemic control at clinical diagnosis (fig 1). A phase is then entered during which most patients are normoalbuminuric. However, after approximately 1...
متن کاملRenoprotection by Telmisartan versus Benazepril in Streptozotocin Induced Diabetic Nephropathy
Diabetic nephropathy (DN) is one of the major causes of end stage renal disease. Angiotensin converting enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB) are preferred for delaying progression of DN. This study compared the preventive renal effects of telmisartan (10 mg/kg, p.o.), an ARB that completely blocks angiotensin action, and benazepril (5 mg/kg, p.o.), an ACE inhibitor, whi...
متن کاملDPP-4 inhibitors-renoprotection in diabetic nephropathy?
There is no doubt that rates of chronic kidney disease are escalating and that this rise is the main contributor to the increasing prevalence of diabetic nephropathy. It is also clear that the increase in kidney failure continues despite tight blood glucose and blood pressure control, as well as renin-angiotensin system blockade. In response, research into novel therapies to treat diabetic neph...
متن کاملOptimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study.
OBJECTIVE We evaluated the optimal dose of the angiotensin II receptor antagonist candesartan cilexetil for renoprotection as reflected by short-term changes in albuminuria in hypertensive type 2 diabetic patients with nephropathy. RESEARCH DESIGN AND METHODS A total of 23 hypertensive patients with type 2 diabetes and nephropathy were enrolled in this double-blind randomized cross-over trial...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nephrology Dialysis Transplantation
سال: 2002
ISSN: 1460-2385
DOI: 10.1093/ndt/17.8.1413